Xilio Therapeutics (XLO) Operating Leases (2020 - 2026)

Xilio Therapeutics has disclosed Operating Leases across 7 years of filings, most recently posting $5.3 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $5.3 million, down 20.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 20.85% YoY), and the FY2025 annual result was $5.6 million, down 19.31% from the prior year.
• Operating Leases came in at $5.3 million for Q1 2026 at Xilio Therapeutics, down from $5.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.9 million in Q1 2022 to a low of $5.3 million in Q1 2026.
• The 5-year median for Operating Leases is $7.9 million (2024), against an average of $7.8 million.
• Across the five-year window, Operating Leases slipped 8.6% in 2022 and retreated 20.85% in 2026, its largest moves.
• Xilio Therapeutics' Operating Leases stood at $9.2 million in 2022, then fell by 11.39% to $8.1 million in 2023, then slipped by 14.59% to $7.0 million in 2024, then declined by 19.31% to $5.6 million in 2025, then slipped by 6.36% to $5.3 million in 2026.
• The last three Operating Leases figures came in at $5.3 million (Q1 2026), $5.6 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.